September 28-29, 2026 | San Francisco, CA USA


May 7-8, 2026 | Amsterdam, the Netherlands

JOIN OUR MAILING LIST

Connecting Clinical Insight, Cutting-Edge Research, and Drug Development

REQUEST BROCHURE FOR USA EVENTSPEAKING OPPS FOR USA EVENT
REQUEST BROCHURE FOR EUROPE EVENTSPEAKING OPPS FOR EUROPE EVENT

About the Summit

ARROWHEAD’S ANNUAL PAIN THERAPEUTICS SUMMIT, taking place in San Francisco on September 28-29, 2026, is the US’s premier pain conference covering the field of pain research and therapeutics. We're thrilled to be bringing a new Pain Therapeutics Summit to Europe in 2026. This event will be taking place in Amsterdam, the Netherlands on May 7-8, 2026.

Leaders from the biopharmaceutical industry, academia and government attend this conference to learn about the latest advances in the treatment of various types of pain and to network with colleagues from industry, academia, clinical research organizations, and government.

This conference provides attendees with thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products.

Explore cutting-edge research, emerging drug targets, clinical trial strategies, and breakthrough pain management approaches. Engage in insightful discussions on preclinical and clinical developments, regulatory challenges, and novel pain biomarkers.

Key Subjects Covered at this Event

fa fa-arrow-right

Clinical Trial Study Design

Experts will discuss innovative trial methodologies, including adaptive designs, patient stratification strategies, and regulatory considerations.

fa fa-arrow-right

Trends in Pain Research

This event covers the latest trends, including the role of non-opioid analgesics, emerging biologics, precision medicine approaches, and regulatory challenges in pain drug development.
fa fa-arrow-right

Novel Pain Drug Targets

Experts from industry & academia will explore groundbreaking research into new molecular pathways, receptors, and mechanisms driving pain.

fa fa-arrow-right

Genetic Components of Pain

Our speakers will explore how genetic insights are shaping the future of pain drug development, from personalized medicine approaches to novel analgesic targets.
fa fa-arrow-right

Emerging Pain Drug Candidates

Industry/academic leaders and scientists will explore the latest breakthroughs in emerging pain drug candidates, discussing clinical progress, regulatory considerations, and challenges
fa fa-arrow-right

Pain Biomarkers

Leading experts will explore the latest advancements in pain biomarker discovery, validation, and clinical application. Discussions will highlight how emerging biomarker technologies are shaping the future of precision pain medicine.

2025 Featured Speakers

David Hewitt, MD
Chief Medical Officer

Allay Therapeutics

Ursula Wesselmann, MD, Ph.D.
Professor of Anesthesiology

University of Alabama at Birmingham

Tony Yaksh, Ph.D.
Professor, Anesthesiology & Pharmacology

UC San Diego

Suma Gopinathan, MD
VP, Clinical Development

Lexicon Pharmaceuticals

Todd Bertoch, MD
Chief Medical Officer/Pain

Cenexel JBR

R. Michael Gendreau, MD, Ph.D.
Chief Medical Officer

Dogwood Therapeutics

Why You Should Attend

Partnering Software & Meetings

Easily schedule meetings with our partnering system in order to maximize your time at the event. Schedule one-to-one meetings in advance and stay connected after the event.

Discover & Learn

Learn about the latest developments in the field of pain drug development and discover what innovative new therapies are driving investment and clinical development

CRO Service Providers

Meet with and/or re-connect with exhibitors and service providers and learn about the latest tools and resources driving pain drug development and future research trends.

Past Sponsors & Exhibitors

worldwide
cenexel
blackbox
vince
fuji
chdr
vertex
celeri

What Past Attendees Have to Say

The meeting to attend if you want to understand pipellne pain therapies and study methods.
John Markman, Vice Chair for Research, Professor of Neurosurgery and Neurology, University of Rochester
I enjoyed the experience and thought the program was a lovely balance of topics across advances in the development space and in the laboratory. The ease to meet and speak to people was also excellent.
Nick Andrews, Instructor and Manager, Boston Children's Hospital/Harvard Medical School
As a small company in nonclinical development of our non-opiate pain medication, I found the Pain Summit to be uniquely valuable, for several reasons. First, the quality and level of speakers was exceptionally good, and brought our thinking to the highest possible level. Second, the mix of NIH policy, senior clinical researchers, and industry contacts was also very good. Third, the way the Pain Summit was structured, there was time to introduce ourselves to key players. This was one of the best conferences I have ever attended, and I look forward to 2019.
Constance McKee, President & CEO, Manzanita Pharmaceuticals
I found the conference not only very informative but also entertaining, with very high quality speakers.
David Yeomans, Professor & Director of Pain Research, Stanford University
It is a nice snapshot of scientific activity and a look at what may be on the horizon in the pain space.
Nicole McGrew, Project Director, INC Research
This is always a delightful and informative session.
Steve Shulman, Assistant Clinical Professor of Anesthesiology & Pain Medicine, Rutgers-NJMS
Greatest importance of this meeting is challenging participants at every level (discovery through clinical development) on conducting optimally validated research to speed up quality drug development.
Gerard Marek, Executive Medical Director, Astellas
From a student perspective, I really thought this conference was valuable and eye-opening. Now I have some ideas on how to conduct better research, and have networked with many professionals at the Summit. Would highly recommend to both students and working professionals.
Esther Eom, Pharmacy Student, University of Maryland
Outstanding meeting of many experts focused on new preclinical and clinical approaches to pain management. Lots of valuable insights and new directions to follow.
Michael G. Palfreyman, Chief Scientific Officer, Amorsa Therapeutics
The conference was a very well balanced session with high quality, innovative attendees, informative sessions and great organization. I'm excited for next year's conference.
Christopher Frankiewicz, Research Scientist, Chromocell Corporation

The Arrowhead Summit is a comprehensive mix of the latest in pre-clinical, mechanistic work in pain drug development along with a nice overview of current clinical trial advancements in this therapeutic area.

Paul Blahunka, Global Development Project Leader, Astellas Pharma
I thought your meeting was a great success. Many members of our team commented that it was one of the most informative meetings they have been to in a very long time. Congratulations on its success.
Todd Bertoch, Chief Medical Officer, JBR Clinical Research
Excellent meeting to present data on innovative analgesic development programs. Also, the meeting provides valuable opportunities for networking with KOLs.
Stephen A. Cooper, Advisory Board Member, JBR Clinical Research

A great meeting to get to know those on the forefront of pain development.

Mike Royal, EVP, Clinical & Regulatory Affairs, Sorrento Therapeutics
Excellent high level conference on development of novel analgesic therapeutics - and the challenges in achieving success in this field.
Srdjan Nedeljkovic, Associate Professor, Pain Management, Harvard Medical School
This was a truly unique assemblage of throught leaders in pain research and investigators doing cutting edge research
Joseph Foss, Founder, Neurotherapia
The meeting was excellent and even better than the one I attended 2 years ago in San Diego. I believe that the Washington DC location provides the best opportunity to gather speakers from industry, academia, and Government. I thought the quality of the speakers was very good and I heard very positive comments also from several of the other attendees. For AnaBios it was also a good opportunity to develop some good business leads, so we are happy about the event potential return.
Andre Ghetti, Chief Executive Officer, AnaBios Corporation
Well-paced conferences with lots of opportunity to socialize Perfect size for connecting with and interacting with others!
Nina Weishaupt, Associate Director, Biology (In Vivo), Xenon Pharmaceuticals
Great opportunity to learn what's new in pain drug development in a small group with plenty of opportunity to network and meet colleagues/experts.
Ana Maria Mendes Cerdeira, VP Global Commercial Early Assets, Grunenthal AG Switzerland
This is my first year to attend this conference - very informative with great speakers & NIH strong support/participation.
Leslie Shen, Professor of Pathology, Texas Tech University Health Science Center

Who Has Attended

Abbott Laboratories | Acura Pharmaceuticals | Adolor Corporation | Adynxx Inc. | Aestus Therapeutics | Afferent Pharmaceuticals | AIT Laboratories | Alder Biopharmaceuticals | Algos Preclinical Services | Alta Life Sciences LLC | Ameritox | Amgen | Anabios Corporation | Analgesic Solutions | Anvyl LLC | Archimedes Pharma | Arcion Therapeutics | Array Biopharma | Astellas Pharma Europe | AstraZeneca | Atallanta Therapeutics | Atlantic Pharmaceuticals Inc | Avigen | Benitec Biopharma | BioAssets Development Corporation | Biogen | BioLineRx | Bionomics | BlackBox Bio | bvBiovail | BioVasc Inc. | Brigham & Women's Hospital | Cacti Therapeutics | Cadence Pharmaceuticals | Camargo Pharma Services | Cambridge Consultants Ltd. | Cara Therapeutics | Cardiome Pharma Corp. | Carnegie Mellon University | Celeri Health | Celgene Corp. | Cenexel | Cephalon, Inc. | CG Pharmaceuticals | ChanTest | Chesapeake Research Group | Chromocell Corporation | Cleveland Clinic | Clinical Trial Centers | Clinsys Clinical Research | CNS Drug Consulting | CNSBio Inc. | COLLEGIUM Pharma | Covidien | CRI Lifetree | CRI Worldwide | CrystalGenomics, Inc. | Cubist Pharmaceuticals | DARA BioSciences, Inc | Decision Line Clinical | Defined Health | Dendreon Corporation | Depomed | Doloromics | Domain Associates | Dr. Kade Pharma GmbH | Dr. Reddy's Laboratories | Dr. Vince Clinical Research | DURECT Corporation | Eicosis | Elanco Animal Health | Eli Lilly & Co | Endevica Bio | EprivA Therapeutics | Ethypharm USA | Eurand | Eurofins Prod Safety Labs | FDA | Forest Research Institute | Franklin Pharmacy | FujiFilm Irvine Scientific | Futuro Clinical Trials | Gateway Clinical Trials | Genentech | Genzyme | GIST | GlaxoSmithKline | Glenmark Therapeutics Inc. | Grünenthal GmbH | GVK Biosciences | GW Pharma | Halia Therapeutics | Harvard Medical School | Harvard University | Hope in Pain | Hospira, Inc. | Hydra Biosciences | i3 Research | Icagen | ICON Development | I-Flow, LLC | Imperial College London | Indiana University | INFARMED, .I.P. | Integrated Circle of Care Inc. | Ironwood Pharmaceuticals | Isis Pharmaceuticals | J. Bolen Group, LLC | Janssen Pharmaceuticals | Janssen Research | Javelin Pharmaceuticals | Jennersville Hospital | Johnson & Johnson Pharmaceutical | KAI Research Inc. | KCI | King Pharmaceuticals | Koneska Health | Labopharm Inc. | Lexicon Pharmaceuticals | Lotus Clinical Research | Lpath | Mass. General Hospital | McGill University | McLean Hospital | MD Biosciences | Mebias Discovery | MedImmune | Medtox Laboratories | Medtronic | Merck & Co., Inc. | Millipore | Mitsubishi Tanabe | Molekule | MRC Technology | National Institute of Neurological Disorders & Stroke | National Institutes of Health | Natixis Bleichroeder | Nektar Therapeutics | NeurAxon | Neurocrine Biosciences | NeuroDiscovery Group | Neuromed | Newron Pharma | NINR, NIH | NMS Labs | North Star Consulting | NovaBay Pharma | Noveida | Noven Pharmaceuticals | Nuvo Research | Nycomed | NYU School of Medicine | Ohio Pain Center | Omneuron, Inc. | Orexo AB | Origin BioMed Inc. | Ormskirk Hospital | Pacira Pharmaceuticals | Pain Ceptor Pharma | Pain Insights, Inc. | Pain Research Forum | PainReform | Pappas Ventures | PAREXEL International | Parmedics | Pfizer VMRD | PharmacoFore | PharmaNet-i3 | Pharmidex | Phosphagenics | Pinney Associates | Plumeria Therapeutics | PLX Pharma | Pollak Clinical Research Consulting | Precise Clinical Research | Premier Research | Prescription Drug Research Center | Product Safety Labs | PsychoGenics Inc. | Purdue Pharma | QRx Pharma | Radical Group | RAFT Pharmaceuticals | Regeneron | Regeneron Pharmaceuticals | ResearchPoint | RHO | Ricerca Biosciences | RoxRo Pharma | Rutgers University | Salk | Sangamo Therapeutics | sanofi Aventis | Schwarz BioSciences | SCOLR Pharma | Scripps Research Institute | Sepracor | Shaare Zedec Medical Center | Shanghai Pharma Biotherapeutics | Shire Pharmaceuticals | Solimar Therapeutics, Inc. | South Rampart Pharma | Sparian Biosciences | St. Louis University | Stanford Pain Medicine Center | Stanford University | Stanford University School of Medicine | Studylog Systems | Sungsil University | Sunovion Pharmaceticals| Susquehanna Financial | Synergenics, LLC | Synergy Clinical Research | Syntaxin Ltd | Takeda Pharmaceutical Company | Temple Univ. Beasley School of Law | Temple University School of Pharmacy | Teva Pharmaceuticals | The May Day Fund |The Pain Treatment Center of the Bluegrass | The Scripps Research Institute | Theorem Clinical Research | TheraQuest Biosciences | Theravance | Toray Industries | Trevena Inc. | Trillium Medical Ventures | Trinity Partners | Tris Pharma | U. Iowa Carver College of Med., Dept. of Pharmacology & Anesthesia | UC Davis | UCSD | UCSF | UMDNJ | University of Adelaide | University of Arizona | University of California San Francisco | University of California, Irvine | University of Colorado | University of Kentucky | University of Miami | University of Minnesota | University of Pittsburgh | University of Rochester Medical Center | University of Tokyo | US FDA | US Pain Foundation | UTSW | Vertex Pharmaceuticals | Victory Pharma | Vince and Associates Clinical Research | Vivozon, Inc | VM Pharma | Washington University | Washington University in St. Louis | WEX Pharmaceuticals | Worldwide Clinical Trials | Wright State University School of Medicine | Wyeth | Wyeth Research | Xalud Therapeutics | Xanodyne Pharmaceuticals | Xenome | Xenon Pharmaceuticals Inc. | XenoPort | Zalicus | Zogenix

About Us

Our conferences offer more than simply presentations; we offer an experience that encompasses learning, networking and professional growth. We focus on bringing life sciences industry professionals together to help move research forward. 
READ MORE

Contact Us

For general information about the conference, please contact us at:
This email address is being protected from spambots. You need JavaScript enabled to view it.
+866.945.0263
PO Box 96, Chanhassen, MN 55317 USA

PRIVACY POLICY